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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of malignancies with a
nearly equal incidence and mortality rates in patients. Pancreatic stellate cells (PSCs) are critical players in PDAC
microenvironment to promote the aggressiveness and pathogenesis of the disease. Dysregulation of microRNAs
(miRNAs) have been shown to play a significant role in progression of PDAC. Earlier, we observed a PSC-specific
downregulation of miR-29a in PDAC pancreas, however, the mechanism of action of the molecule in PSCs is still to
be elucidated. The current study aims to clarify the regulation of miR-29a in PSCs and identifies functionally
important downstream targets that contribute to tumorigenic activities during PDAC progression.
Methods: In this study, using RNAseq approach, we performed transcriptome analysis of paired miR-29a
overexpressing and control human PSCs (hPSCs). Enrichment analysis was performed with the identified
differentially expressed genes (DEGs). miR-29a targets in the dataset were identified, which were utilized to create
network interactions. Western blots were performed with the top miR-29a candidate targets in hPSCs transfected
with miR-29a mimic or scramble control.
Results: RNAseq analysis identified 202 differentially expressed genes, which included 19 downregulated direct
miR-29a targets. Translational repression of eight key pro-tumorigenic and -fibrotic targets namely IGF-1, COL5A3,
CLDN1, E2F7, MYBL2, ITGA6 and ADAMTS2 by miR-29a was observed in PSCs. Using pathway analysis, we find that
miR-29a modulates effectors of IGF-1-p53 signaling in PSCs that may hinder carcinogenesis. We further observe a
regulatory role of the molecule in pathways associated with PDAC ECM remodeling and tumor-stromal crosstalk,
such as INS/IGF-1, RAS/MAPK, laminin interactions and collagen biosynthesis.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: jkota@iu.edu
1Department of Medical and Molecular Genetics, Indiana University School of
Medicine, Indianapolis, IN, USA
3The Melvin and Bren Simon Cancer Center, Indiana University School of
Medicine, Indianapolis, IN, USA
Full list of author information is available at the end of the article
Dey et al. BMC Cancer          (2020) 20:651 
https://doi.org/10.1186/s12885-020-07135-2
(Continued from previous page)
Conclusions: Together, our study presents a comprehensive understanding of miR-29a regulation of PSCs, and
identifies essential pathways associated with PSC-mediated PDAC pathogenesis. The findings suggest an anti-
tumorigenic role of miR-29a in the context of PSC-cancer cell crosstalk and advocates for the potential of the
molecule in PDAC targeted therapies.
Keywords: Pancreatic cancer, PDAC, PSCs, microRNA, miR-29a, Protein interaction network, RNAseq, Desmoplasia,
Tumor microenvironment, ECM
Background
Despite considerable advancement in the knowledge of
pathogenesis and therapeutics of pancreatic ductal
adenocarcinoma (PDAC) in recent years, the disease
continues to remain as one of the deadliest malignancies.
PDAC ranks as the seventh leading cause of cancer-
related deaths worldwide [1] and the fourth in the
United States [2]. This rapidly metastatic cancer is char-
acterized by abundant desmoplastic reactions around
pancreatic tumors mediated by the pancreatic stellate
cells (PSCs) [3–5]. PSCs remain in quiescent state in
normal pancreas, with a low extracellular-matrix (ECM)
producing capacity. During pancreatic injury or
inflammation, PSCs are activated by pro-inflammatory
cytokines and growth factors to differentiate into myofi-
broblasts, expressing alpha smooth muscle actin (α-
SMA) [3, 6, 7]. The transformed and activated stromal
PSCs interact with the tumor cells, proliferate and pro-
duce ECM proteins and growth factors promoting fibro-
sis, pancreatitis and pancreatic cancer [4, 8, 9].
MicroRNAs (miRNAs) are a class of small (~ 22 nucleo-
tide long), non-coding RNAs in multicellular organisms,
which modulate key cellular mechanisms of proliferation,
metabolism and apoptosis via post-transcriptional regula-
tion of hundreds of genes [10]. miRNAs are initially gener-
ated as primary transcripts (pri-miRNA) from inter- and
intragenic chromosomal regions predominantly via RNA
polymerase II mediated transcription, and are then further
processed by the Drosha RNase III enzyme to produce
short hairpin pre-miRNAs [11]. Pre-miRNAs are exported
to the cytoplasm by exportin 5, where they are further
processed by the exonuclease III enzyme Dicer, in a com-
plex, to generate mature miRNA. Mature miRNA, along
with Agonaute 2, forms an RNA-dependent silencing
complex and binds to the 3′-UTRs of the target gene
mRNAs with imperfect complementarity to cause their
degradation or translational suppression [11, 12]. Accu-
mulating evidences have shown the involvement of miR-
NAs in regulation of pathological processes of variety of
diseases including oncogenesis [12–14]. Studies have fur-
ther demonstrated the association of dysregulated miR-
NAs in stromal cells with progression of different types of
cancer, including pancreatic cancer, indicating the poten-
tial of miRNAs in developing targeted therapies [15–20].
In our previous work, we found microRNA-29a (miR-
29a) to be pre-dominantly an anti-fibrotic molecule in
PDAC, where miR-29a was significantly downregulated
in activated PSCs and fibroblasts of murine and human
PDAC as compared to normal pancreas, resulting in en-
hanced stromal extracellular matrix (ECM) deposition in
PDAC microenvironment [21]. In addition, co-culture of
pancreatic cancer cells with miR-29a overexpressing
PSCs resulted in significant reduction in colony forma-
tion ability of the cancer cells and stromal deposition
[21]. Thus, given the anti-fibrotic and tumor suppressive
role of miR-29a in PSC-mediated PDAC progression, in
the current study, we sought to decipher the mechanism
of miR-29a in PSC regulation by identifying some of the
key downstream target genes of the molecule, which also
have critical functional implications in stromal remodel-
ing and PDAC pathogenesis. Here we show for the first
time that miR-29a concatenates genes belonging to key
pathways associated with PDAC microenvironment, in-
dicating the importance of the molecule in PSC-
mediated PDAC stromal accumulation, suggestive of the
potential of miR-29a as a therapeutic target for
normalization of PDAC stroma.
Methods
Cell culture
Primary human pancreatic stellate cells (hPSCs) (3830,
ScienCell Research Laboratories Carlsbad, California)
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM, 11965092, Life Technologies, Carlsbad, CA)
supplemented with 10% FBS in a humidified 5% CO2 in-
cubator at 37 °C. hPSCs were authenticated using short
tandem repeat profiling, and were regularly tested for
mycoplasma contamination (MycoAlert, Lonza). All cells
used in this study were less than passage 9.
Transfection
To overexpress miR-29a, hPSC cells were seeded at 1 X
105 cells/well in 6 well-plates for 24 h and transfected with
control (CN-001000-01, GE Dharmacon, Lafeyette, CO)
or miR-29a mimic (C-300504-07, GE Dharmacon, Lafey-
ette, CO) using DharmaFECT 1 Reagent (T-2001-01, GE
Dharmacon, Lafeyette, CO) following manufacturer’s
instructions. Total protein or RNA was isolated 48 h post-
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transfection for western blot or qPCR analyses,
respectively.
RNA extraction
Total RNA from cultured cells were extracted using the
RNeasy plus Mini kit (74,134, Qiagen, Venlo,
Netherlands) following manufacturer’s protocol. The
concentration and purity of the extracted RNAs were
measured using a Nanodrop 2000 Spectrophotometer
(Thermo Fisher Scientific, Carlsbad, CA).
RNAseq
For RNAseq, the quality and integrity of the extracted
RNA were evaluated by a Bioanalyzer 2100 (Agilent
technologies, CA). Samples with RNA Integrity Number
(RIN) > 7.0 were used for RNAseq. cDNA libraries were
prepared using the TruSeq RNA library kit (Illumina
Inc., San Diego, CA). The libraries were amplified and
then sequenced on an Illumina Hiseq.2000 instrument
(San Diego, CA) with 100 bp paired end reads per sam-
ple. The quality of the sequence data was analyzed using
FastQC [22]. The reads were mapped to the human gen-
ome (hg38) using STAR (v.2.5) [23]. Uniquely mapped
sequencing reads were assigned to genes based on
Gencode 25 using featureCounts (v1.6.2) [24]. Genes
with read count per million (CPM) < 0.5 in two or more
samples were filtered out and gene expression profiles
were normalized using trimmed mean of M values
(TMM) method. Differentially expressed genes (DEGs)
were assessed by cutoff p-value of less than 0.05 after
false discovery rate (FDR) adjustment with amplitude of
fold change (FC) of gene expression greater than 2 linear
FC.
Target prediction, functional enrichment and network
analysis
Conserved miR-29a target genes were obtained using
TargetScan (v7.1). The hypergeometric model was
adopted to identify the overlap between DEGs and miR-
29a predicted targets.
Functional enrichment analysis of the gene ontology
(GO) terms and KEGG pathway analysis were performed
using R package to investigate the biological functions
and pathways of the identified genes. The protein-
protein interaction networks of the genes were explored
using the STRING database, version 11 [25].
Quantitative real time PCR (qRT-PCR)
RNA was reverse transcribed to cDNA using High
capacity cDNA Reverse Transcription kit (4368814,
Thermo Fisher Scientific, Carlsbad, CA) with random
primers for genes or custom primer pool for miRNA
(Thermo Fisher Scientific, Carlsbad, CA). To measure
mature miR-29a expressions, TaqMan qRT-PCR
reactions were set up using TaqMan Fast Advanced
Mastermix (4444557, Applied Biosystems Foster City,
CA) with TaqMan probe and primers for mature
miR29a (002112, Applied Biosystems, Foster City, CA)
or U6 snRNA (001973, Applied Biosystems, Foster
City, CA). To assay the mRNA levels of genes, qRT-
PCRs were performed with PowerUp SYBR Green
Mastermix (A25742, Applied Biosystems, Foster City,
CA) and custom primers Table S1). miRNA and
mRNA qRT-PCR were normalized to U6 and ACTB
respectively. Samples were run in triplicates in a 10 μl
final volume using ABI 7500 Real-Time PCR machine
with standard settings. Relative expressions were ana-
lyzed using ΔΔCT method.
Western blot
Protein lysates were prepared with RIPA Buffer (PI-
89900, Thermo Fisher Scientific, Carlsbad, CA) and
quantified using BCA Protein Assay Kit (23,225,
Pierce Biotechnology, Waltham, CA). Equal amounts
of total protein were loaded onto NuPAGE 4–12%
Bis-Tris Gels (NP0323, Invitrogen, Carlsbad, CA).
After electrophoresis, the gels were electrotransferred
onto polyvinylidene fluoride membranes, blocked with
5% dry non-fat milk and incubated overnight at 4 °C
with specific primary antibodies. The membranes
were washed and then probed with corresponding
HRP conjugated goat anti-mouse (31,430, Thermo
Fisher Scientific, Carlsbad, CA) or goat anti-rabbit
(31,460, Thermo Fisher Scientific, Carlsbad, CA) anti-
bodies at 1:5000 dilution. To develop the blots, ECL
detection kit (34,096, Thermo Fisher Scientific, Carls-
bad, CA) was utilized and the images were captured
on an Amersham Imager 600 (GE Healthcare, Chi-
cago, IL). Densitometry analysis was performed using
Image J software to quantify each protein band, which
were then normalized against loading control GAPD
H. The primary antibodies used in this study were
anti-IGF-1 (ab9572, Abcam, Cambridge, MA), anti-
COL5A3 (PA5–77257, Thermo Fisher Scientific,
Carlsbad, CA), anti-E2F7 (ab56022, Abcam,
Cambridge, MA), anti-MYBL2 (PA546845, Thermo
Fisher Scientific, Carlsbad, CA), anti-ITGA6 (3750,
Cell Signaling Technology, Danvers, MA), anti-
CLDN1 (4933S, Cell Signaling Technology, Danvers,
MA), anti-ADAMTS2 (3485, Cell Signaling Technol-
ogy, Danvers, MA), and anti-GAPDH (MA5–15738,
Thermo Fisher Scientific, Carlsbad, CA).
Statistical analysis
All data were expressed as mean ± standard error of the
mean (SEM) of three independent experiments. Statis-
tical analysis was performed by ANOVA or Student’s t
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test. Statistical significance is indicated as *p < 0.05 or
**p < 0.01 or ***p< 0.001.
Results
RNAseq and identification of DEGs
RNAseq libraries were constructed using RNAs from
control and miR-29a overexpressing hPSCs to generate
global miR-29a targetome. Overexpression of miR-29a
in the transfected hPSCs was verified by qPCR (Fig. 1a).
Sequencing was performed with 2X 100 bp paired end
reads. This yielded sequence reads ranging from 17 to
34 million pairs, of which 90–92% aligned to the hg19
genome assembly (Table 1). Quantile normalization with
log2 transformation of number of counts per million
(CPM) was performed and quality of raw sequencing
reads and depth were verified for differential expression
testing between the control and miR-29a overexpressing
PSCs. For identification of DEGs, genes were plotted in
a volcano plot by their log10 P values with FDR (q value)
< 0.05 against log 2 fold change (FC) (Fig. 1b). This iden-
tified 90 downregulated and 106 upregulated genes with
FDR < 0.05 and log FC < -1 or > + 1 respectively (Table
S2). Next, inputting the DEG IDs into the TargetScan
database, we identified 20 putative direct miR-29a tar-
gets among the identified DEGs- 19 of which were
downregulated and one was upregulated (Fig. 1c).
Among the downregulated miR-29a targets, IGF-1 ex-
hibited the highest fold change, followed by COL5A3,
E2F7, CLDN1, and MYBL2. DPYSL3 was the only up-
regulated target that met the screening criteria.
GO term enrichment and pathway analysis of
downregulated genes
GO analysis of the DEGs with an FDR < 0.05 revealed
that the downregulated (target and non-target) genes
were significantly enriched in several PDAC relevant
biological processes such as regulation of mitosis and
cell cycle, cell migration and motility, cellular adhesion,
cell proliferation, extracellular matrix organization and
cytokine signaling (Table 2). Among the 19 miR-29a
predicted downregulated target genes, IGF-1, CLDN1
and ITGA6 were enriched in regulation of cell motility/
migration (Table 2). COL5A3, ADAMTS2, ITGA6,
LAMC1 and IGF-1 associated with mechanisms of ECM
remodeling. While ITGA6 and IGF-1 are negative regu-
lators of apoptosis, E2F7 and MYBL2 contribute to the
regulation of cell cycle (Tables 2 and 3). In addition, the
pathways enriched for miR-29a overexpressing PSCs in-
cluded IGF-1 signaling, Tp53 signaling, collagen path-
way, integrin-laminin interactions, RAS/MAPK signaling
and cytokine signaling as depicted in Table 3. Thus, the
GO and pathway enrichment analyses indicate that miR-
29a modulates effectors of signaling pathways associated
with crucial mechanisms of ECM remodeling and
tumor-stromal crosstalk, suggesting a potential role of
the molecule in PSC-mediated regulation of PDAC
tumor microenvironment (TME).
Validation analysis using qPCR and Western blots
Among the identified DEGs from the RNAseq, we se-
lected all 19 down- and one upregulated miR-29a targets
Fig. 1 RNAseq analysis of miR-29a overexpressing hPSCs. a qPCR analysis for miR-29a expression in hPSCs transfected with miR-29a mimics (29a
OE) as compared to hPSCs transfected with scramble control (CTRL). Numerical data are represented as average fold change (ΔΔCT) ± standard
error of the mean (SEM); ***p < 0.001; n = 6. b Volcano plot of DEGs (log FC > 1 or < − 1, FDR < 0.05) in hPSC cells overexpressing miR-29a
compared to controls. The horizontal axis represents log2 fold change between miR-29a overexpressing and control hPSCs. The negative log10 of
the q-value is plotted on the vertical axis. Each point on the graph represents one gene. c A hierarchically clustered heatmap showing the
expression patterns of the differentially expressed miR-29a direct target genes in the three replicates for each of miR-29a overexpressing (OE1,
OE2 and OE3) and control (Control 1, Control 2, Control 3) mRNAs. Red and blue represent up- and downregulation respectively, and the color
intensity represents the level of fold changes
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along with a subset of 24 additional DEGs to validate
the RNAseq results using qRT-PCR. The expressions
of 43 of the 44 tested genes well matched between
the RNAseq and qPCR analyses (Table 4, Fig. 2a).
Based on pathway analyses and available literature,
IGF-1, COL5A3, CLDN1, E2F7, MYBL2, ITGA6 and
ADAMTS2 were the most prominent miR-29a targets
involved with one or more essential signaling mecha-
nisms associated with TME regulation (Tables 2 and
3). Therefore, we next sought to find if miR-29a had
a translational impact on these genes in PSCs. Our
western blot analysis showed that protein levels of
each of the seven selected targets were significantly
diminished in miR-29a overexpressing PSCs (Fig. 2b).
The most robust depletion was observed for ITGA6,
followed by ADAMTS2 and IGF-1 respectively. All
these three significantly downregulated target genes
associate with ECM remodeling or fibrotic mecha-
nisms. ITGA6 is a member of the integrin family that
are heterodimer cell surface receptors comprising of α
and β chains [26]. Alpha 6 containing integrins (α6/
β4 and α6/β6) are the primary receptors for laminins,
including laminin1 (LAMC1), a major ECM
component [26]. Further, ECM in interaction with
cellular integrins forms a scaffold, and plays essential
role in cell proliferation, migration/invasion and sur-
vival [26]. ADAMTS2, belonging to the ADAM metal-
lopeptidase with thrombospondin type 1 motif
(ADAMTS) family, is responsible for processing of
collagen type I, II, III and V precursors (pro-colla-
gens) into mature collagen by excision of amino-
propeptide, which is essential for generation of
collagen monomers and assembly of mature collagen
fibrils [27, 28]. Inhibition of ADAMTS2 has been
shown to reduce stromal deposition and modulate
TGF-β1 signaling [27, 29]. IGF-1 plays an essential
role in fibrotic processes in different organs including
pancreas, liver and lung [30–32]. Recent reports dem-
onstrate the association of IGF-1 in PSCs to promote
stromal accumulation and basal growth rate in PDAC
[33], as well as miR-29a-mediated regulation of the
gene [34]. Interestingly, each of the seven tested tar-
gets have been shown to exhibit pro-tumorigenic ef-
fects. Together, the observations suggest an anti-
fibrotic and tumor suppressive function of miR-29a in
PSC mediated PDAC pathogenesis.
Table 1 RNA-Seq read counts and mapping statistics. Ctrl (Control) and miR-29a OE (overexpressing) represent hPSCs transfected
with Control and miR-29a mimics respectively. R1, R2 and R3 are the three experimental replicates
Sample ID Total Reads Mapped Reads Mapped High Quality Reads Read Mapping Ratio Percentage mapped to gene
hPSC Ctrl R1 38,372,969 35,691,075 35,333,674 92.07% 90.27
hPSC Ctrl R2 25,288,719 22,628,590 22,389,149 88.53% 90.09
hPSC Ctrl R3 18,759,093 16,958,204 16,698,047 89.01% 92.21
hPSC miR-29a-OE R1 36,899,783 34,288,605 33,965,913 92.05% 90.89
hPSC miR-29a-OE R2 20,971,993 18,594,180 18,318,771 87.35% 91.59
hPSC miR-29a-OE R3 33,726,399 29,480,256 29,128,167 86.37% 90.30
Table 2 Most relevant biological processes associated with downregulated genes in miR-29a overexpressing hPSCs
Biological Process Gene Name Ratio p value
Positive regulation of cell proliferation IGF1a; KIF14; IL1B; ESM 1; BCL2; KIF20B 6/490 0.024382
Cell division CENPF; SPDL1; KIF14; SKA3; KIFC1; NEK2; SKA1; KIF18B; CENPE; CDCA5; KIF20B 11/346 4.69E-07
Regulation of G2/M transition of mitotic cell cycle CENPF; KIF14; PLK4; NEK2; PLK1 5/80 3.2E-05
Negative regulator of extrinsic apoptotic pathway ITGA6a; IGF1a 2/35 0.011085
Cell adhesion LAMC1a; PCDH9a; PODXL; ITGA2; PCDH1; AJAP1 6/454 0.017486
Cell matrix adhesion COL5A3a; ITGA6a; ADAMTS12; ITGA2 4/95 0.000932
Focal adhesion assembly ITGA2; BCL2 2/27 0.006695
Positive regulation of fibroblast proliferation IGF1a; E2F1 2/49 0.021029
Collagen fibril organization COL5A3a; ADAMTS2a 2/46 0.018671
Extracellular matrix organization COL5A3a; LAMC1a; ITGA6a; ITGA2; ABI3BP; PTX3 6/229 0.000624
Cell junction organization ITGA6a;CLDN1a; LAMC1a; ITGA2 4/37 0.002963
Positive regulation of cell migration CLDN1a; ITGA6a; IGF1a; PLAU; F2RL1; PODXL; LRRC15; IL1B 8/224 8.23E-06
Positive regulation of inflammatory response ITGA2; IL1B 2/75 0.046007
Positive regulation of IL-6 secretion F2RL1; IL1B 2/33 0.009895
a miR-29a direct targets
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Network interactions of the downregulated miR-29a
targets
To determine if the identified downregulated miR-29a
direct target genes formed a network of interactions, we
next analyzed the genes utilizing the Search Tool for the
Retrieval of Interacting Genes/Proteins (STRING) data-
base. We included a few additional nodes to construct
the network. We observed three distinct networks in the
interactome, which consisted of insulin/IGF, RAS/
MAPK and laminin signaling pathways (Fig. 3).
IGF-1, belonging to the IGF family members, is one of
the key regulators of the insulin/IGF pathway. IGF-1 is a
direct downregulated miR-29a target in our dataset,
which interacts with other effectors of the pathway
including IGF-1R, INSR, IGFBP4 IGFBP5 and FSTL1
(Fig. 3). Interestingly, one of the oncogenes PTPN1 in
the pathway is also a predicted direct miR-29a target,
however, our RNAseq data did not show differential ex-
pression for this gene with miR-29a overexpression,
which could be an effect specific to the PSCs. Nonethe-
less, the insulin/IGF signaling is a key driver in tumor-
stromal interactions, metastasis and PDAC progression
[33]. IGF-1 secreted by activated PSCs and fibroblasts in
PDAC stroma via IGF-1 receptor (IGF-1R) promote can-
cer cell migration, invasion and metastasis [33, 35]. In
fact, the RAS/MAPK pathway identified in our study
consisted of interactions of IGF-1 and IGF-1R with other
genes in the pathway including NRAS, HRAS, KRAS,
SOS1 and RAF1. It is well documented that the MAPK
signaling cascade bridges the crosstalk between ECM-
mediated extracellular signaling through growth factors
and their receptors such as IGF-1/IGF-1R, and subse-
quent intracellular response to allow cancer cell prolifer-
ation and migration [36]. IGF-1 bound activated IGF-1R
phosphorylates insulin receptor substrates (such as IRS1,
IRS2 and Shc). The Src homology 2 (SH2) domains of
these substrates are recognized by signaling molecules to
activate the intracellular effectors such as RAS, RAF and
SOS and the RAS/MAPK pathway [37, 38]. Interestingly,
in our previous study, we observed significant downreg-
ulation of NRAS with miR-29a overexpression in PDAC
cell lines [39]. In the current study, miR-29a overexpres-
sion also resulted in moderate downregulation of NRAS
in PSCs (logFC = − 1.01), however the role of NRAS in
PSCs is unknown. Nonetheless, it is apparent that miR-
29a modulates extracellular IGF-1/IGF-1R signaling in
PSCs, and intracellular NRAS expression in pancreatic
cancer cells, which indicates a functional role of the
molecule in tumor-stromal crosstalk via insulin/IRF
-RAS/MAPK signaling mechanism in PDAC.
The identified interactome further consisted of three
miR-29a targets namely ITGA6, LAMC1 and FSTL1 that
associate with laminin interactions, which are salient to
pancreatic ECM and desmoplasia [40–42]. LAMC1 en-
codes for laminin γ1 chain isoform, which are essential
non-collagenous ECM glycoproteins, integral to base-
ment membrane assembly and crucial for intra- and
extracellular communication to modulate cellular behav-
ior [43]. Laminin interactions, including that of LAMC1,
have been shown to promote oncogenesis via processes
including cancer cell migration, differentiation and me-
tastasis [44–47]. Cytoplasmic laminin expression corre-
lates with poor patient prognosis in pancreatic cancer
[48] and has been shown as one of the most efficient
ECM proteins to promote cell adhesion-mediated drug
resistance [49]. Further, ECM-integrin interactions are
found to be crucial for adhesion-mediated drug and re-
sistance to chemotherapy [50, 51].
Discussion
In our previous studies, we observed significant loss of
miR-29a in several PDAC cell lines [21, 39]. In addition,
Table 3 Pathways enriched for downregulated genes in miR-29a overexpressing hPSCs
Pathway name Genes P value
Cell cycle GINS1; PLK4; TOP2A; GINS2; BLM; CDCA5; PLK1; HJURP; CASC5; ESCO2; CENPA; AURKB; SKA1;
CENPE; CENPF; EXO1; E2F1; E2F7a; NEK2; MYBL2a; SPDL1
R = 683; G = 21, p
value = 2.07E-10
Tp53 pathway BLM; EXO1; FANCD2; E2F1; SPDL1; E2F7a; AURKB R = 259; G = 7; p value
= 0.02074
Signaling by Ras mutants NRASa; IQGAP3 R = 54; G = 2; p
value=6.41E-04
IGF pathway NRASa; LAMC1a; IGF1a; FSTL1a; PAPPA2 R = 127; G = 5; p
value=0.032048
Laminin interactions ITGA2; ITGA6a; LAMC1a R = 31; G = 3; p
value=0.003216579




COL5A3a; ADAMTS2a; ITGA2 R = 84; G = 3; p
value=0.04578
R = the number of reference genes in the category; G = number of genes in the gene set for each category; a miR-29a direct targets
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Table 4 qPCR validation of differentially expressed genes
Gene Symbol RNAseq qRT-PCR
logFC p value FDR logFC
Downregulated
IGF1a −1.59 0.00 0.01 −1.48
COL5A3a −1.50 8.80E-07 0.00 −1.32
CLDN1a −1.49 0.00 0.01 −1.89
E2F7a −1.49 1.21E-06 0.00 −2.12
MYBL2a −1.35 1.42E-05 0.00 −1.92
TET3a −1.24 3.92E-05 0.00 −1.13
PCDH9a −1.2 3.02E-05 0.00 −1.18
EMP1a −1.19 4.09E-06 0.00 − 2.18
ITGA6a −1.18 0.00 0.012 −2.01
XXYLT1a −1.13 7.18E-05 0.00 −1.08
BCL7Aa −1.12 0.00 0.02 −1.80
ADAMTS2a −1.11 2.52E-05 0.00 −1.08
DCLK3a −1.10 0.00 0.02 −1.32
LAMC1a −1.09 9.16E-07 0.00 −1.32
KIAA1549La −1.07 1.43E-05 0.00 −1.12
PRMT6a −1.07 3.82E-05 0.00 −1.19
KDELC1a −1.03 6.87E-06 0.00 −1.83
NRASa −1.01 2.61E-05 0.00 −1.15
FSTL1a −1.0 1.16E-06 0.00 −2.3
PPP1R14C −3.54 0.00 0.02 −2.58
ESM 1 −1.97 0.00 0.01 −1.41
BCL2 −1.90 0.00 0.03 −1.30
PLAU −1.51 4.93E-07 0.00 −2.17
IL1B −1.26 9.42E-05 0.00 −2.88
EXO1 −1.22 0.00 0.02 −1.62
ITGA2 −1.10 4.23E-06 0.00 −2.17
IQGAP3 −1.09 0.00 0.01 −1.20
BLM −1.06 0.00 0.01 −1.04
E2F1 −1.03 0.00 0.02 −1.20
AURKB −1.02 5.01E-05 0.00 −1.92
Upregulated
DPYSL3a 1.09 3.21E-06 0.00 1.01
PYGM 3.58 0.00 0.01 3.64
CXCL5 2.40 5.34E-07 0.00 1.98
NEFL 1.98 0.00 0.02 1.26
GNAO1 1.82 0.00 0.03 1.44
TNFRSF10C 1.62 0.00 0.03 1.20
HLA-DMA 1.51 0.00 0.03 2.06
ITGA7 1.46 0.00 0.02 1.65
FBXO32 1.41 1.06E-05 0.00 1.31
PIK3AP1 1.31 8.41E-05 0.00 1.53
HERC6 1.15 0.00 0.03 1.04
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miR-29a was globally repressed in PDAC tumor tissues,
as well as in a PSC- and epithelial cell- specific manner
[21]. We further demonstrated that TGF-β1 via SMAD3
signaling negatively regulates miR-29a expression in
PSCs and upregulates several ECM proteins including
collagens, laminin and fibronectin [21]. In the current
study, using RNAseq, we characterize the mechanism
and pathway interactions by which miR-29a contributes
to PSC-mediated regulation of ECM and tumor-stromal
crosstalk. This will allow for a comprehensive under-
standing of the therapeutic applicability of the molecule
in the context of PDAC stroma.
RNAseq analysis with miR-29a overexpressing PSCs
and controls identified a number of DEGs, which in-
cluded predicted direct and indirect targets of the mol-
ecule. Because miRNAs primarily regulate genes either
by mRNA decay or translational repression, we focused
on the direct targets that were downregulated with
miR-29a overexpression. We validated the translational
repression of the targets namely IGF-1, COL5A3,
CLDN1, E2F7, MYBL2, which exhibited the highest
fold changes in the RNAseq dataset, along with ITGA6
and ADAMTS2, which had functional relevance in stro-
mal regulation. Our western blot analysis indicated the
highest repression of ITGA6, ADAMTS2 and IGF-1
protein levels with miR-29a overexpression in PSCs
(Fig. 2b). Among these identified direct targets, associ-
ation of IGF-1 and COL5A3 with PSCs in PDAC has
been reported previously [33, 52]. Network analysis
with the targets identified three overlapping pathways
related to IGF, RAS/MAPK signaling and laminin inter-
actions. IGF-1 secreted by activated PSCs and CAFs via
sonic hedgehog pathway activates IGF-1R in cancer
cells triggering phosphorylation of insulin-receptor or
Table 4 qPCR validation of differentially expressed genes (Continued)
Gene Symbol RNAseq qRT-PCR
logFC p value FDR logFC
HIST1H1C 1.12 0.00 0.04 −1.18
IGFBP3 1.06 5.82E-06 0.00 0.89
HIST2H2BE 1.03 0.00 0.018 0.65
amiR-29a direct targets
Fig. 2 Validation of miR-29a direct target. a Relative fold changes estimated by qPCR analysis for the top miR-29a candidate target genes of
ITGA6, ADAMTS2, IGF-1, COL5A3, CLDN1, E2F7 and MYBL2 in hPSCs transfected with miR-29a mimics (29a OE) compared with cells transfected
with scramble control (CTRL). Numerical data are represented as average fold change (ΔΔCT) ± standard error of the mean (SEM); **p < 0.01; n =
3. b Total protein harvested from the hPSCs transfected with scramble control (CTRL) or miR-29a mimics (29a OE) 48 h post-transfection were
subjected to western blot analysis for miR-29a candidate targets of ITGA6, ADAMTS2, IGF-1, COL5A3, CLDN1, E2F7 and MYBL2. GAPDH was used
as the loading control. Quantification of band intensities normalized to GAPDH. Quantification of band intensities normalized to GAPDH and
relative to respective controls are represented as ± SEM; n = 3, *p < 0.05, **p < 0.01, ***p< 0.001 (right). Uncropped blots are shown in Additional
file 3: Fig. S1
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Src substrates to promote PDAC metastasis via intracellu-
lar pathways such as RAS/MAPK [37, 53]. In addition,
high IGF-1 with low IGFBP3 expressions associated with
enhanced risks for PDAC [54]. Expectedly, patients with
advance clinical stages (II and III) of PDAC had higher
levels of IGF-1R and low IGFBP3, and exhibited poor
prognosis [54]. Interestingly, the IGF-1R expressions in
these patients associated with high stromal abundance,
suggesting the regulation of tumor-stromal crosstalk via
IGF/IGF-1R signaling [54]. Another identified miR-29a
target CLDN1 is a tight junction protein that facilitates
cell-ECM communication and EMT in various cancer
types [55–57]. The gene is shown to be a contributor in
tumor-stroma crosstalk in pancreatic cancer [58]. Al-
though the regulation of CLDN1 in PSCs has not been re-
ported previously, studies have shown the gene to be
under the regulation of IGF-1 signaling [59, 60]. Upregula-
tion of collagens, including COL5A3, is a salient feature of
fibrosis and malignant tumor stroma, including that in
PDAC [52, 61, 62]. Collagens are abundantly expressed in
PDAC ECM; and collagen V, by binding with α2β1 in-
tegrin receptors, stimulates migration, proliferation
and metastasis in PDAC [63]. Interestingly, ADAM
TS2, another identified miR-29a downregulated target,
primarily functions to process collagens I, II, III and V
precursors into mature molecules [27, 28]. The gene
promotes fibrosis via activation of TGF-β signaling
[64]. Evidently, miR-29a plays an anti-fibrotic role in
PDAC by influencing ECM deposition via modulation
of multiple targets in the collagen pathway. In addition
to these genes that directly regulate tumor-
microenvironment and desmoplasia, the top targets
identified from our dataset consisted of the two add-
itional genes E2F7 and MYBL2, which play essential
roles in cell cycle regulation. E2F7 associates with
poor patient outcome in several types of cancer in-
cluding PDAC [65–67] and has been shown essential
for mouse embryonic survival [68]. Inhibition of E2F7
enhanced G1 phase percentage in prostate cancer re-
ducing cellular proliferation [67]. Similarly, MYBL2 is
Fig. 3 Network analysis for miR-29a predicted targets. Network interaction of miR-29a targets identified by RNAseq was constructed using the
STRING database. The genes highlighted in black circles are the predicted miR-29a targets
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a transcription factor which promotes cell prolifera-
tion and differentiation by fostering cell cycle entry
into S and M phases, and is dysregulated in types of
cancer [39, 69, 70]. A recent study demonstrated the
regulatory role of MYBL2 in promoting PDAC desmo-
plasia and PSCs’ growth through sonic hedgehog and
adrenomedullin via paracrine and autocrine signaling
[71], however the role of the gene in PSCs has not
been reported. A negative feedback regulatory mech-
anism between miR-29a and MYBL2 influencing the
activation of PSCs is possible, but this requires future
validation. Nonetheless, the identified set of miR-29a
target genes exhibit a pro-fibrotic and tumorigenic
function in PDAC desmoplasia and progression via
multiple targeted pathways, although PSC-specific
function of some of the identified target genes such as
E2F7, CLDN1, MYBL2 and ADAMTS2 has not been
studied previously. Together, the observations in the
current study signify that overexpression of miR-29a
may lead to inhibition of PSC-induced pro-fibrotic
and desmoplastic effects by targeting these genes to
impair signaling mechanisms such as sonic hedgehog,
IGF, RAS/MAPK, collagen metabolism and laminin
pathways, and perturbing their normal cellular re-
sponses to promote PDAC progression.
As mentioned above, IGF-1 signaling axis is a key
mechanism that promotes PDAC tumor-stromal crosstalk
and drug resistance. In our RNAseq dataset, we observed
the most robust downregulation of the IGF-1 gene among
all miR-29a targets. It is possible that in addition to IGF-1
alone, miR-29a regulates IGF-signaling via modulating
multiple components of the pathway in PSCs, such as in-
direct regulation of genes including IGF-1R, INSR and
direct targeting of some others. It is worthy to note that
MYBL2 and E2F7 are miR-29a targets that are at the
functional convergence of p53-IGF-1 pathways. Stromal
p53 has been implicated as a key component that repro-
grams activated pancreatic and hepatic stellate cells to
transform them into quiescent states [72, 73]. Depletion
of p53 in stromal cells caused faster and more aggressive
tumor development with enhanced invasion and metasta-
sis of cancer cells, suggesting a paracrine mechanism of
p53 in tumor progression [74, 75]. In addition, studies
have reported the occurrence of inactivating p53 muta-
tions in fibroblastic stromal cells and their association in
promoting tumor progression and cancer cell metastasis
in types of carcinogenesis [74], although the molecular
mechanisms are still unclear. MYBL2 is a downstream ef-
fector of the p53 pathway [69]. With p53 mutations,
MYBL2 repression is uncoupled allowing enhanced bind-
ing of the molecule with MuvB and FOXM1 leading to
activation of mitotic genes [69, 76]. FOXM1 is an essential
component of Akt signaling, which functions both in the
context of tumor stroma and cancer cells to promote
tumorigenesis [77–80]. Interestingly, Akt pathway is
under inverse regulation of IGF-1 signaling [79, 81, 82].
Similarly, E2F7 is a crucial transcription factor, which pro-
motes E2F1-p53 dependent apoptosis and cell-cycle arrest
[68, 83]. In our RNAseq data with miR-29a overexpress-
ing PSCs, we found E2F1 as one of the indirect downregu-
lated targets. In addition, E2F7 has also been shown to be
activated by Akt signaling in carcinomas [83–85]. Al-
though the exact mechanisms of MYBL2 and E2F7 in
PSCs is still to be understood, our results suggest that
dysregulation of miR-29a in PSCs derepresses genes such
as IGF-1, MYBL2 and E2F7, which may in turn disrupt
stromal p53 regulation, promoting PSC-mediated tumor
proliferation.
GO analysis showed that the direct and indirect miR-
29a downregulated targets were enriched in crucial cel-
lular and molecular functions associated with PDAC
stromal remodeling and proliferation. The biological
processes consisted of those related to cell cycle regula-
tion, collagen formation, ECM organization and immune
signaling (Table 2). Our study further identified inter-
connected networks comprising of essential pathways in
PDAC stromal regulation and desmoplasia (Table 3). Al-
though a single miRNA is known to target hundreds of
genes, resulting in their post- transcriptional repression,
based on the functional network of the differentially
expressed targets, the predominant phenotypic effect of
a miRNA can be systematically analyzed in a context-
specific manner. Our analysis using PSCs identifies a
number of miR-29a target genes that are crucial players
in PDAC stromal remodeling and tumor-stromal cross-
talk, suggesting the importance of the molecule in their
pathway regulations to modulate PDAC microenviron-
ment and tumor progression.
Conclusion
The current study is the first to use RNAseq platform
for a comprehensive characterization of the PSC tran-
scriptome under the regulation of miR-29a. In PDAC,
activated PSCs foster cancer cell migration via desmo-
plastic reaction characterized by increased collagen, lam-
inin and other ECM deposition resulting in fibrosis. Our
data identified altered expressions of a number of novel
genes under miR-29a regulation, including IGF-1,
COL5A3, CLDN1, E2F7, MYBL2, ITGA6, ADAMTS2,
and related pathways such as insulin-IRF, RAS/MAPK,
laminin and collagen pathways in PSCs that are dysregu-
lated or associate with PDAC tumor-stromal crosstalk
and ECM remodeling. Given the functional relationship
among the identified miR-29a targets in our PSCs data-
set, it is likely that restoration of miR-29a in PSCs will
dwindle or escalate the interconnected tumor-
suppressive/pro-tumorigenic networks respectively in
PDAC microenvironment, causing global regulation of
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the network functions to hinder the disease progression.
Since our conclusions are primarily based on computa-
tional analysis, future investigations aimed to delineate
the mechanistic relationship of miR-29a, its targets and
related pathways in PSCs as well as cancer cells, would
allow for a deeper comprehension of the associated
pathological changes in tumor-stromal crosstalk in
PDAC. This would be essential to assess the therapeutic
modalities of miR-29a and its target networks in the dis-
ease. Nonetheless, our data in the current report identifies
novel genes and networks under the regulation of miR-
29a in PSCs, bolstering an anti-tumorigenic function of
the molecule in the context of PDAC stroma. These find-
ings suggest that targeted upregulation of miR-29a may
hold great therapeutic value in efficacious PDAC
treatment.
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